KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $35.8 million.

  • Travere Therapeutics' Change in Cash rose 76877.12% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.5 million, marking a year-over-year increase of 16910.65%. This contributed to the annual value of $359000.0 for FY2024, which is 11022.21% up from last year.
  • Per Travere Therapeutics' latest filing, its Change in Cash stood at $35.8 million for Q3 2025, which was up 76877.12% from $13.3 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Change in Cash peaked at $99.7 million during Q1 2023, and registered a low of -$90.5 million during Q2 2023.
  • Over the past 5 years, Travere Therapeutics' median Change in Cash value was $4.1 million (recorded in 2024), while the average stood at $1.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 128468.25% in 2021, then plummeted by 68115.52% in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' Change in Cash stood at $15.4 million in 2021, then tumbled by 681.16% to -$89.6 million in 2022, then increased by 3.99% to -$86.1 million in 2023, then surged by 125.71% to $22.1 million in 2024, then skyrocketed by 61.69% to $35.8 million in 2025.
  • Its Change in Cash stands at $35.8 million for Q3 2025, versus $13.3 million for Q2 2025 and $3.4 million for Q1 2025.